CASI Pharmaceuticals Inc (CASI)


Stock Price Forecast

March 22, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading CASI Pharmaceuticals Inc chart...

About the Company

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.

CEO

Wei-Wu He

Exchange

NASDAQ

Website

www.casipharmaceuticals.com

$37M

Total Revenue

176

Employees

$24M

Market Capitalization

-1.40

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CASI News

CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients

on MSN ago, source:

CASI Pharmaceuticals Inc (NASDAQ:CASI) and BioInvent International AB announced preliminary efficacy data for BI-1206 in ...

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

1mon ago, source:

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced ...

CASI Mar 2024 10.000 call

11d ago, source: Yahoo Finance

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent ...

CASI Pharma Posts Positive BI-1206 Interim Phase 1 Data In R/R INHL; Stock Climbs In Pre-market

13d ago, source:

Shares of CASI Pharmaceuticals, Inc. (CASI) were gaining more than 49 percent in pre-market activity on Nasdaq after the ...

CASI stock rises on positive interim data from early stage trial for its NHL treatment in China

on MSN ago, source:

CASI Pharmaceuticals (Nasdaq: CASI) shares rose 25% at $6.36 after company and BioInvent International AB (BINV) announced preliminary encouraging data ...

AI Might Shape What Comes Next for Apple

18d ago, source: Hosted on MSN

After Nvidia's impressive $750 billion surge this year thanks to booming demand for AI chips, investors are on the hunt for ...

Aptevo Therapeutics: Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

19h ago, source:

SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprie ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...